The Mood Disorders lab has conducted and continues to conduct clinical research trials investigating treatments for depression and bipolar disorder. See below for our various active, future, and past study activities.
You can also contact us at our Toll Free# (833) 630-0015 or email us at depression-research@med.umich.edu for more information.
Depression is a serious but common condition that affects how you think, feel, and carry out your daily activities. We are studying an investigational oral medication to see if it reduces symptoms of moderate-to-severe depression in adults.
The Shoreline Study is a Phase 3, open-label, 1-year study of the safety and need for re-treatment with SAGE-217 in adults with major depressive disorder (MDD), as assessed by the Hamilton Depression Rating Scale (HAM-D).
If you are interested in participating, learn more about it through University of Michigan Health Research (link: https://UMHealthResearch.org/#studies/HUM00194150
The IDEA study offers people self-help tools to improve their symptoms of depression and promote wellbeing such as a smartphone app, a computer-based online program, or an educational website and try to understand whether the tools are helpful to them.
Sixty depressed patients will be asked to select one electronic Mental Health (e-MH) resource from three offered in this pilot study. A Depression Care Manager will also be paired with patients, in part to motivate continued use of the resources, since lack of persistent use of e-MH resources has been a barrier. This study will provide real-world data on the implementation and effectiveness of e-health resources in a traditional healthcare delivery model.
If you are interested in participating, learn more about it through University of Michigan Health Research (link: https://umhealthresearch.org/#studies/HUM00174081)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of an investigational medication, (SPRAVATOTM)
A clinical trial for Esketamine Nasal Spray, SPRAVATOTM, as a standalone therapy for adult participants with treatment-resistant depression (TRD). Esketamine nasal spray (SPRAVATOTM) is currently approved in the United States for use with an oral antidepressant for the treatment of TRD in adults.
If you are interested in participating, learn more about it through University of Michigan Health Research (link: https://UMHealthResearch.org/#studies/HUM00192384)
To evaluate the therapeutic effect of MK-1942 in participants with treatment resistant depression.
This is a Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety MK-1942 in adult participants with treatment resistant depression on stable antidepressant therapy. The study population will consist of male and female participants aged 18 to 65 years with a primary diagnosis of moderate-to-severe MDD who are currently experiencing a depressive episode and who have not adequately responded to 2 to 4 courses of antidepressant therapy (including the current course of antidepressant therapy) despite sufficient dose and duration.
The purpose of the study is to test whether a software (Clinical Decision Aid) assists physicians make better decisions and treatment recommendations for patients with depression.
The study takes the form of a two-arm, prospective, open-label, controlled, randomized trial to test the effectiveness and safety of the use of a CDA (clinical decision aid) by physicians treating adults with major depressive disorder (MDD). Up to 50 participants to be recruited at UM site.
The purpose of the Bio-K study is to find out if the medication known as ketamine, can help the symptoms of depression in people living with major depression, bipolar disorder I or II. More specifically, we want to find out if some people have a better response to ketamine treatments than others and if we can predict that response (biomarkers).
A multi-site clinical trial looking at biomarkers of response to treatment with Intravenous ketamine, for adult patients with treatment refractory major depression or bipolar depression.
To understand subjective experiences of participants using IV ketamine for treatment-resistant depression that go beyond clinically administered scales.
A sub-study of the Bio-K study, where enrolled participants of the Bio-K Study were asked about their subjective experiences while using IV ketamine and the effects of the treatment in their life after study completion. Participants were asked questions via Zoom using an in-depth interview guide.
The Department of Psychiatry offers several research opportunities. Some studies may offer compensation and/or treatment.
